Cytokinetics (CYTK) announced its support of a three-year initiative led by the American Heart Association, AHA, to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy, HCM. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Appoints New Executive VP and CLO
- Cytokinetics price target raised to $87 from $82 at RBC Capital
- Cytokinetics price target raised to $90 from $80 at B. Riley
- Cytokinetics presents additional data from MAPLE-HCM
- Promising Potential of Cytokinetics’ Aficamten Drives Buy Rating Amid Anticipated U.S. Approval